Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

Title
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 10, Pages 1583-1586
Publisher
Springer Nature
Online
2012-04-18
DOI
10.1038/bjc.2012.144

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now